Literature DB >> 20693196

Cutaneous lupus erythematosus: recent lessons from animal models.

M Ghoreishi1, J P Dutz.   

Abstract

Cutaneous lupus erythematosus (CLE) may present as a clinically heterogeneous group of lupus-specific skin lesions that have common histopathological findings. Determination of the immunopathological sequence of events in this group of disorders has been challenging for dermatologists and immunologists but is vital for therapeutic targeting. We review animal models in which different aspects of immune alteration in CLE have been addressed. The MRL/lpr mouse develops spontaneous skin disease with some features of CLE. Study of this strain and related gene-manipulated strains has revealed roles for multiple cytokines, including interleukin (IL)-6, IL-18, and IL-21, in disease pathogenesis. A role for the growth factor colony stimulating factor 1 and the inflammatory protein high-mobility group box 1 has also been suggested. We discuss potential novel treatment options suggested by these models.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20693196     DOI: 10.1177/0961203310370045

Source DB:  PubMed          Journal:  Lupus        ISSN: 0961-2033            Impact factor:   2.911


  7 in total

1.  Ruxolitinib Attenuates Cutaneous Lupus Development in a Mouse Lupus Model.

Authors:  Emilie S Chan; Leal C Herlitz; Ali Jabbari
Journal:  J Invest Dermatol       Date:  2015-03-19       Impact factor: 8.551

Review 2.  Animal models of skin disease for drug discovery.

Authors:  Pinar Avci; Magesh Sadasivam; Asheesh Gupta; Wanessa Cma De Melo; Ying-Ying Huang; Rui Yin; Rakkiyappan Chandran; Raj Kumar; Ayodeji Otufowora; Theodore Nyame; Michael R Hamblin
Journal:  Expert Opin Drug Discov       Date:  2013-01-08       Impact factor: 6.098

3.  Monoclonal antibody against macrophage colony-stimulating factor suppresses circulating monocytes and tissue macrophage function but does not alter cell infiltration/activation in cutaneous lesions or clinical outcomes in patients with cutaneous lupus erythematosus.

Authors:  K Masek-Hammerman; E Peeva; A Ahmad; S Menon; M Afsharvand; R Peng Qu; J B Cheng; J Syed; Y Zhan; S P O'Neil; S Pleasic-Williams; L A Cox; D Beidler
Journal:  Clin Exp Immunol       Date:  2015-11-09       Impact factor: 4.330

4.  Fn14 deficiency protects lupus-prone mice from histological lupus erythematosus-like skin inflammation induced by ultraviolet light.

Authors:  Jessica Doerner; Samantha A Chalmers; Adam Friedman; Chaim Putterman
Journal:  Exp Dermatol       Date:  2016-12       Impact factor: 3.960

Review 5.  Lupus erythematosus revisited.

Authors:  Annegret Kuhn; Joerg Wenzel; Marc Bijl
Journal:  Semin Immunopathol       Date:  2015-12-04       Impact factor: 11.759

6.  TWEAK/Fn14 Signaling Involvement in the Pathogenesis of Cutaneous Disease in the MRL/lpr Model of Spontaneous Lupus.

Authors:  Jessica L Doerner; Jing Wen; Yumin Xia; Karin Blecher Paz; David Schairer; Lan Wu; Samantha A Chalmers; Peter Izmirly; Jennifer S Michaelson; Linda C Burkly; Adam J Friedman; Chaim Putterman
Journal:  J Invest Dermatol       Date:  2015-03-31       Impact factor: 8.551

7.  Deletion of IL-18 Expression Ameliorates Spontaneous Kidney Failure in MRLlpr Mice.

Authors:  Bastian Schirmer; Dirk Wedekind; Silke Glage; Detlef Neumann
Journal:  PLoS One       Date:  2015-10-14       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.